Published in Antimicrob Agents Chemother on February 01, 1988
Aminoglycoside use in renal failure. Indian J Nephrol (2010) 0.77
Microbiologic aspects of chronic ambulatory peritoneal dialysis. Kidney Int (1983) 2.66
KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG. J Pharm Sci (1964) 2.19
A simple and safe technique for continuous ambulatory peritoneal dialysis (CAPD). Trans Am Soc Artif Intern Organs (1978) 2.17
Phase and antigenic variation of pili and outer membrane protein II of Neisseria gonorrhoeae. J Infect Dis (1986) 1.90
Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease. Am J Med (1977) 1.22
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis (1987) 1.19
Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther (1982) 1.07
Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther (1983) 1.00
Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1987) 0.95
Peritoneal pharmacokinetics of gentamicin in man. Clin Nephrol (1983) 0.87
Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther (1986) 0.86
Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1981) 0.85
Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. J Clin Psychiatry (1999) 2.61
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 2.17
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis (1998) 1.52
Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. JPEN J Parenter Enteral Nutr (1991) 1.44
MUSCLE EXTRACT IN THE TREATMENT OF ANGINA PECTORIS AND INTERMITTENT CLAUDICATION. Br Med J (1930) 1.39
Outcomes of weight-based heparin dosing based on literature guidelines and institution individualization. Pharmacotherapy (2000) 1.39
Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med (2000) 1.21
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother (1997) 1.20
Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother (1995) 1.15
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther (2000) 1.12
The absolute bioavailability of oral melatonin. J Clin Pharmacol (2000) 1.09
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr (1984) 1.04
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother (2006) 1.01
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99
Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother (1997) 0.98
Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther (1986) 0.98
Single daily dose of aminoglycosides--a concept whose time has not yet come. Clin Infect Dis (1997) 0.95
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother (1998) 0.95
Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol (1989) 0.92
Methicillin-resistant Staphylococcus aureus outbreak: a consensus panel's definition and management guidelines. Am J Infect Control (1998) 0.90
Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients. Antimicrob Agents Chemother (1989) 0.90
Solubility and stability of amphotericin B in human serum. Ther Drug Monit (1989) 0.89
Gentamicin dosing requirements in patients with acute pancreatitis. Surgery (1988) 0.87
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol (2001) 0.87
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics (1998) 0.87
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther (1998) 0.85
A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol (2001) 0.85
Evaluation of moxalactam. Clin Pharm (1983) 0.85
Reassessment of theophylline toxicity. Serum concentrations, clinical course, and treatment. Arch Intern Med (1987) 0.84
Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults. J Infect Dis (1997) 0.84
Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother (1992) 0.84
The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. J Clin Pharmacol (1987) 0.84
Developmental pharmacokinetics of moxalactam. Antimicrob Agents Chemother (1983) 0.83
Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther (2007) 0.83
Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital. Arch Intern Med (1986) 0.83
Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit (1987) 0.82
Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. Pharmacogenetics (2001) 0.82
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther (1998) 0.82
Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med (1993) 0.82
KINI: a one compartment intravenous pharmacokinetic analysis program. Comput Methods Programs Biomed (1994) 0.82
The effect of whole virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis (1988) 0.81
Barbiturate and nonbarbiturate sedative hypnotic intoxication in children. Pediatr Clin North Am (1986) 0.81
Stability of an extemporaneous formulation of injectable cholecalciferol. Am J Hosp Pharm (1981) 0.81
Effect of variation in infusion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate. J Antimicrob Chemother (1991) 0.80
Comparative effects of cefoxitin and cefotetan on vitamin K metabolism. Antimicrob Agents Chemother (1988) 0.80
The effect of split virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis (1985) 0.80
Prolonged nausea and vomiting associated with buprenorphine. Pharmacotherapy (1991) 0.80
Inhibition of theophylline elimination by diltiazem therapy. J Clin Pharmacol (1987) 0.79
Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. Int J Clin Pharmacol Ther (2009) 0.79
The cephalosporin antibiotics. Pediatr Clin North Am (1983) 0.79
Lack of effect of atenolol on the pharmacokinetics of theophylline. Br J Clin Pharmacol (1988) 0.79
Salicylate hepatitis: a complication of the treatment of Kawasaki's disease. Am J Hosp Pharm (1981) 0.78
Distribution of orthopaedic surgeons, lawyers, and malpractice claims in New York. Clin Orthop Relat Res (1997) 0.78
Development of meningitis during therapy with cefamandole. Pediatrics (1981) 0.78
Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol (1989) 0.78
Methods of minimising the cost of aminoglycoside therapy to hospitals. Pharmacoeconomics (1993) 0.76
Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents. Antimicrob Agents Chemother (1996) 0.75
A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med (1999) 0.75
Single daily dosing of aminoglycosides--A community standard? Clin Infect Dis (2000) 0.75
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther (1999) 0.75
Menstrual cycle and renal clearance. Clin Pharmacol Ther (1991) 0.75
Is the phenytoin-enteral feeding formula interaction a myth? Nutr Clin Pract (1996) 0.75
Lack of effect of atenolol and nadolol on the metabolism of theophylline. Br J Clin Pharmacol (1990) 0.75
Waste generation of drug product samples versus prescriptions obtained through pharmacy dispensing. Pharmacotherapy (2000) 0.75
MUSCLE EXTRACT TREATMENT OF SOME GRAVE VASCULAR DISEASES. Br Med J (1931) 0.75
Absence of tobramycin pharmacokinetic and creatinine clearance variation during the menstrual cycle: implied absence of variation in glomerular filtration rate. J Clin Pharmacol (1989) 0.75
The effect of activated charcoal on phenytoin pharmacokinetics. Ann Emerg Med (1990) 0.75
Analysis of the practice of nutrition support pharmacy specialists. Pharmacotherapy (1996) 0.75
Use of intravenous iron dextran injection in children receiving total parenteral nutrition. Am J Dis Child (1981) 0.75
Prophylaxis and treatment of childhood rickets with parenteral cholecalciferol. JPEN J Parenter Enteral Nutr (1984) 0.75
Constant diazepam infusion in the treatment of continuous seizure activity. Drug Intell Clin Pharm (1984) 0.75
Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis. Clin Pharm (1989) 0.75
Carbamazepine-associated exfoliative dermatitis. Clin Pharm (1983) 0.75
Disposal of CAPD waste in the community. Perit Dial Int (1991) 0.75
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics (1999) 0.75
Comparison of cefaclor and trimethoprim-sulfamethoxazole in the treatment of acute otitis media. Pediatr Infect Dis (1984) 0.75
Pharmacists and infectious diseases specialists. Clin Infect Dis (1998) 0.75
Alterations in gentamicin pharmacokinetics during neonatal exchange transfusion. Dev Pharmacol Ther (1982) 0.75
Lack of effects of diltiazem on digoxin pharmacokinetics. J Clin Pharmacol (1985) 0.75
Why we now have physicians who seek to join RPhs in making pharmacy rounds. Pharm Times (1987) 0.75
Effects of heparin sodium on gentamicin assay measured by fluorescence polarization immunoassay method. Ther Drug Monit (1984) 0.75
Pharmacokinetics of gentamicin during exchange transfusions in neonates. J Pediatr (1980) 0.75
Iron-deficiency anemia in childhood inflammatory bowel disease: treatment with intravenous iron-dextran. JPEN J Parenter Enteral Nutr (1982) 0.75